Missense mutations that alter the DNA-binding domain of the MtrR protein occur frequently in rectal isolates of Neisseria gonorrhoeae that are resistant to faecal lipids

William M. Shafer,1,2 Jacqueline T. Balthazar,1,2 Kayla E. Hagman1 and Stephen A. Morse1

Author for correspondence: William M. Shafer. Tel: +1 404 728 7688. Fax: +1 404 329 2210. e-mail: wshafer@unix.cc.emory.edu

1 Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta GA 30322, USA
2 Laboratories of Microbial Pathogenesis, VA Medical Center (Atlanta), Decatur, GA 30033, USA
3 Sexually Transmitted Diseases Research Laboratory, Center for Disease Control and Prevention, Atlanta, GA 30333, USA

Resistance of Neisseria gonorrhoeae to structurally diverse hydrophobic agents (HAS) has been associated with missense or deletion mutations in the mtrR (multiple transferable resistance Regulator) gene of laboratory-derived strains but their prevalence in clinical isolates was heretofore unknown. Since faecal lipids provide strong selective pressure for the emergence of variants resistant to HAS (HA), the nucleotide sequence of the mtrR gene from rectal isolates of N. gonorrhoeae, which displayed different levels of HA, was determined. Compared to the mtrR gene possessed by the HA-sensitive strain FA19, each clinical isolate contained mutations in the coding and/or promoter regions of their mtrR gene. A missense mutation in codon 45 (Gly-45 to Asp) was the most common mutation found in the strains studied and impacted the structure of the helix-turn-helix domain of the MtrR protein thought to be important in DNA-binding activity. Two clinical isolates bearing a missense mutation in codon 45 also contained a single basepair deletion in a 13 bp inverted sequence positioned within the mtrR promoter region. Introduction of mtrR sequences amplified from the clinical isolates into strain FA19 revealed that acquisition of the single basepair deletion was correlated with high level HA while mutations in the mtrR-coding region provided for an intermediate level of HA.

Keywords: gonococci, transcriptional regulator, missense mutations, antimicrobial agents, Neisseria gonorrhoeae

INTRODUCTION

The genetic control of multi-antibiotic resistance expressed by Neisseria gonorrhoeae, as exemplified by the mtr (multiple transferable resistance) system, is of considerable interest because a single mutation can lead to resistance to not only antibiotics but also antibacterial compounds (e.g. fatty acids and bile salts) that bathe mucosal surfaces. Maness & Sparling (1973) initially described the mtr system and showed that it mediated resistance to a panel of hydrophobic agents (HAS) including drugs, dyes and detergents. Subsequent reports indicated that such resistant strains accounted for 12.5% of all clinical isolates (Morse et al., 1982). Moreover, strains displaying hyper-sensitivity to penicillin and HAS, due to mutations in env loci, often contained a phenotypically suppressed mutation in their mtrR gene (Eisenstein & Sparling, 1978); these strains could serve as genetic donors in the horizontal spread of HA (Shafer et al., 1984).

The mtr system is a multi-gene complex consisting of the mtrR gene, encoding the MtrR transcriptional repressor protein (Pan & Spratt, 1994), and three tandemly linked genes (mtrCDE) that are positioned 250 bp upstream and transcribed divergently from the mtrR gene (Hagman et al., 1995). The mtrCDE genes constitute a single transcriptional unit and encode proteins (MtrC, MtrD and MtrE) similar to the MexAB-OprK membrane proteins of Pseudomonas aeruginosa (Poole et al., 1993a), which mediate bacterial resistance to antibiotics by an efflux-based mechanism (Poole et al., 1993b).

Missense mutations in the mtrR-coding region (Pan &
Spratt, 1994; Hagman et al., 1995), as well as a single basepair deletion in the mtrR promoter region (Hagman et al., 1995), were able to confer HA2 when introduced by transformation into the HA8 strain FA19. Since the frequency and importance of these mutations among clinical isolates was unknown, we determined the nucleotide sequence of mtrR genes from six strains isolated from patients with rectal gonorrhoea. These isolates were chosen for analysis because antibacterial faecal lipids have been proposed to select for HAR variants (Morse et al., 1982). The results revealed that missense mutations that cause radical amino acid substitutions within the proposed DNA-binding domain of the MtrR protein of laboratory-derived strains also occur frequently in HA8 clinical isolates.

**METHODS**

**Gonococcal strains and growth conditions.** The strains employed in this investigation and their levels of resistance to HAs are listed in Table 1. Strains FA171 and BR87 are genetic derivatives of strain FA19 that were constructed in the 1970s (Sparling et al., 1975; Sarubbi et al., 1975). Strain BR87, hypersusceptible to HAs, contains a missense mutation in codon 45 of its mtrR gene (Hagman et al., 1995) that is phenotypically suppressed by an unlinked mutation, em-2 (Sarubbi et al., 1975). The presence of this missense mutation in strain BR87 prompted this investigation. Strain FA171 is a transformant of strain FA19. It was constructed (Sparling et al., 1975) using donor DNA from an HA8 mutant (FA48) derived from an HA hypersusceptible mutant (FA47) of strain FA19 (Sarubbi et al., 1975). Strains AP776, AP1058, AP1169, AP1192, NRL31115 and NRL31376 were rectal isolates obtained from non-partner homosexual men with gonorrhoea. These isolates were obtained in Seattle, Washington during the period of 1978–1980 and were previously found to be resistant to the antibacterial action of faecal lipids (Morse et al., 1982). They exhibited varying levels of resistance to HAs (Table 1). All strains were grown as P+Op+ variants on GCB agar containing glucose and iron supplements (Shafer et al., 1984) under 343% (v/v) CO2 at 37 °C.

**Antimicrobial susceptibility testing.** The minimal inhibitory concentrations (MIC) of the HAs crystal violet (CV), erythromycin (Ery) and Triton X-100 (TX-100) for the strains studied were determined as described previously (Shafer et al., 1984) and are presented in Table 1.

**PCR amplification and DNA sequencing.** A chromosomal DNA sequence encompassing the 633 bp mtrR coding region, 120 bp of sequence information past the translational start codon, and 272 bp of sequence information upstream of the translational start codon was obtained by PCR amplification of chromosomal DNA preparations (McAllister & Stephens, 1993) using the oligonucleotide primers CEL-1 (5’ GACAATGTTC- ATGCCAGATAGG 3’) and KH9#3 (5’ GACGACAGTGCAATGCCAG 3’). PCR amplification was for 30 cycles using a two-step programme consisting of a 1 min denaturation at 95 °C followed by extension at 60 °C. PCR products for use in sequencing and transformation were purified by agarose gel electrophoresis and electrophoretically into TBE buffer (9 mM Tris, 9 mM boric acid, 2 mM EDTA, pH 8.0); at least two independent lots of PCR-amplified DNA were obtained from each strain. DNA sequencing was performed using the above described oligonucleotide primers, labeled with [γ-32P]ATP (NEN DuPont). The AmpliTaq cycle sequencing kit (Perkin Elmer) was used as recommended by the manufacturer.

**Transformation.** A 0.5 ml sample of a culture of strain FA19 (P+) was incubated with 0.05 μg of agarose-gel-purified, PCR-amplified DNA in transformation broth (Shafer et al., 1984) for 0.5 h prior to plating onto GCB agar. After incubation for 5 h at 37 °C under 3-8% (v/v) CO2, transformants resistant to Ery (0-5 μg ml−1) were selected using an agar overlay procedure (Sparling et al., 1975). Transformants were screened for levels of resistance to CV, Ery and TX-100.

**RESULTS**

**Deduced amino acid sequences of MtrR proteins**

The nucleotide sequences of the mtrR-coding regions from the isogenic gonococcal strains FA19, FA171 and BR87, and the clinical isolates CH95 and 3035, were

---

**Table 1. Strains of N. gonorrhoeae and susceptibility to HAs**

<table>
<thead>
<tr>
<th>Strain</th>
<th>Source</th>
<th>MIC* of:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>CV</td>
<td>Ery</td>
</tr>
<tr>
<td>FA19</td>
<td>P. F. Sparling, Dept of Medicine, University of North Carolina</td>
<td>2</td>
<td>0.25</td>
</tr>
<tr>
<td>BR87</td>
<td>1</td>
<td>0.06</td>
<td>0.031</td>
</tr>
<tr>
<td>FA171</td>
<td>Transformant‡</td>
<td>10</td>
<td>2.0</td>
</tr>
<tr>
<td>KH15</td>
<td></td>
<td>10</td>
<td>2.0</td>
</tr>
<tr>
<td>AP776</td>
<td></td>
<td>10</td>
<td>2.0</td>
</tr>
<tr>
<td>AP1058</td>
<td></td>
<td>5</td>
<td>1.0</td>
</tr>
<tr>
<td>AP1169</td>
<td></td>
<td>5</td>
<td>1.0</td>
</tr>
<tr>
<td>AP1192</td>
<td>Clinical isolates</td>
<td>20</td>
<td>2.0</td>
</tr>
<tr>
<td>NRL31115</td>
<td></td>
<td>10</td>
<td>1.0</td>
</tr>
<tr>
<td>NRL31376</td>
<td></td>
<td>10</td>
<td>1.0</td>
</tr>
</tbody>
</table>

* Expressed as μg ml−1 for CV and Ery and mg ml−1 for TX-100.
† The em-2 mutation renders strain BR87 hypersusceptible to HAs (Sarubbi et al., 1975).
‡ Transformant of strain FA19 constructed using a PCR-amplified product from strain FA171 (Hagman et al., 1995).
**Fig. 1.** Deduced amino acid sequences of MtrR proteins. The amino acid sequences for the MtrR proteins from strains FA19 and FA171 are identical. Amino acids are shown in the single letter code. The site of amino acid replacements due to missense mutations in codons 40, 45 and 105 and strains previously determined (Hagman *et al.*, 1995; Pan & Spratt, 1994). This information was used for comparison of their deduced respective MtrR protein sequences with those of the clinical isolates studied herein. As is shown in Fig. 1, the MtrR protein of strain BR87 differed from that of parental strain FA19 by a single amino acid as a result of a missense mutation [GGC (glycine) to GAC (aspartic acid)] in codon 45. This missense mutation is likely to affect MtrR function because it occurs within the second helical domain of the HTH motif, increasing the helical characteristics of the adjacent turn region. The mtrR-coding region from strains CH95 (isolated in Thailand in 1990) and 3035 (isolated in the UK in 1987) were previously shown (Pan & Spratt, 1994) to contain an identical missense mutation in codon 105 that replaced histidine with tyrosine at position 105, which is outside of the HTH motif.

Compared to strain FA19, all six HA^R^ rectal isolates possessed nucleotide differences in their mtrR-coding sequences. Strain NRL31115 was of particular interest because it contained an 11 bp insert (5'-TCTGCGACGAC-3') at nucleotide position 204 that represented an exact duplication of nucleotides 193-203 of the mtrR-coding region. This duplication would result in the production of a protein of 117 amino acids with a C-terminal domain that diverges from the FA19 MtrR sequence at amino acid position 69 (Fig. 1) and is truncated by 73 amino acids (alanine) in the first helical domain of the HTH motif with a hydrophilic amino acid (threonine) (Fig. 1).

**Frequency of a deletion mutation in the mtrR promoter region**

Hagman *et al.* (1995) demonstrated that the MtrR protein possessed by HA^R^ strain FA171 had an identical amino acid sequence to that of its parental strain, FA19 (Fig. 1). However, strain FA171 and the clinical isolate CH95 (Hagman *et al.*, 1995) were found to have a single basepair (A/T) deletion in the 13 bp inverted repeat sequence located within the mtrR promoter region (Fig. 2). An examination of the DNA sequence upstream of the mtrR translational start codon in the six clinical isolates revealed that two (strains AP1169 and AP1192) contained this single base deletion (Fig. 2) in addition to the missense mutation in codon 45.

**Transforming activity of mtrR genes**

In order to verify that the mutations described above were important in determining HA^R^ in gonococci, the mtrR region was amplified by PCR from strains FA19, FA171, NRL31115, AP776, AP1169 and AP1058 and the gel-purified products were used to transform strain FA19 for increased resistance to HA. 5 µg Ery ml^-1^ was used in the selection. With the exception of the negative control PCR product from strain FA19, all PCR products displayed transforming activity (Table 2). The presence of the donor mutations in representative transformants was confirmed by sequencing PCR-amplified DNA products (data not presented).

Representative transformants were scored for levels of cross-resistance to CV and TX-100 and the results (Table 2) showed that the transformants expressed either intermediate or high levels of HA^R^ Differences in levels of HA^R^ expressed by the transformant strains were most apparent with respect to TX-100 resistance (TX-100^B^). Thus, intermediate levels of TX-100^B^ (0-5-20 mg TX-100 ml^-1^) were obtained when the donor DNA possessed only a missense mutation in codon 40 (strain AP776) or codon 45 (strain AP1058) or the nonsense mutation (strain NRL31115). However, donor DNA samples containing the single base deletion in the mtrR promoter
Table 2. Transforming activity of PCR-amplified mtrR genes

<table>
<thead>
<tr>
<th>Donor PCR-DNA</th>
<th>Nonsense or missense mutation</th>
<th>Single bp deletion</th>
<th>Transformation frequency†</th>
<th>MIC* towards transforms of:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CV</td>
</tr>
<tr>
<td>FA19‡</td>
<td>-</td>
<td>-</td>
<td>&lt; 10⁻⁹</td>
<td>NA</td>
</tr>
<tr>
<td>FA171</td>
<td>-</td>
<td>+</td>
<td>4 x 10⁻⁴</td>
<td>10</td>
</tr>
<tr>
<td>NRL31115</td>
<td>+</td>
<td>-</td>
<td>8 x 10⁻⁵</td>
<td>5</td>
</tr>
<tr>
<td>AP776</td>
<td>+</td>
<td>-</td>
<td>4 x 10⁻⁶</td>
<td>5</td>
</tr>
<tr>
<td>AP1058</td>
<td>+</td>
<td>-</td>
<td>5 x 10⁻⁹</td>
<td>5</td>
</tr>
<tr>
<td>AP1169</td>
<td>+</td>
<td>+</td>
<td>6 x 10⁻⁵</td>
<td>10</td>
</tr>
</tbody>
</table>

* Expressed as µg ml⁻¹ for CV and Ery, and mg ml⁻¹ for TX-100. High-level resistance is defined as TX-100 MIC > 16 mg ml⁻¹ and intermediate resistance is defined as TX-100 MIC 0.5-2.0 mg ml⁻¹. NA, Not applicable.
† Transformation frequencies were calculated as transformants per mg DNA per 10⁶ c.f.u. ml⁻¹.
‡ The MIC value for donor strain FA19 is shown in Table 1.

region with (strain AP1169) or without (strain AP171) an accompanying missense mutation in codon 45 were capable of transforming strain FA19 to high level TX-100R (> 16 mg TX-100 ml⁻¹). The level of HA⁺ expressed by transformants obtained with the FA171, NRL31115, AP776 and AP1169 PCR products resembled that of their respective donor strains (Table 1). However, the level of HA⁺ expressed by transformants obtained with the PCR product from strain AP1058 was less than that of the donor strain (Table 2). This difference was more obvious with TX-100R, suggesting that strain AP1058 contained a second but mtr-independent mechanism for resistance to the membrane-damaging action of this detergent. An mtr-independent mechanism for determining levels of gonococcal resistance to faecal lipids, which exert detergent-like action in membranes, has been previously proposed (McFarland et al., 1983) and is supported by this data.

**DISCUSSION**

These results confirm and extend previous studies (Pan & Spratt, 1994; Hagman et al., 1995) that implicated the MtrR protein as a regulator of HA⁺ in gonococci. The similarity between MtrR and certain transcriptional repressors, notably those belonging to the tetracycline repressor family (Brow et al., 1985), have led to the suggestion that MtrR may function to control expression of genes that are responsible for the efflux of HAs. Indeed, our recent studies (Hagman et al., 1995) indicate that MtrR regulates expression of the tandemly linked mtrCDE genes because mutations in the mtrR-coding or upstream sequences results in enhanced levels of the MtrC lipoprotein. MtrC (Hagman et al., 1995) shares more than 40% identity at the amino acid level to the MexA (Poole et al., 1993), AcrA (Ma et al., 1993) and EnvC (Klein et al., 1991) lipoproteins that participate in the efflux of antimicrobial agents from *P. aeruginosa* (MexA) and *E. coli* (AcrA and EnvC).

The missense mutation in codon 45 that we identified in four of the six clinical isolates was identical to that observed previously (Hagman et al., 1995) in a laboratory-derived strain (BR87). Since this mutation is phenotypically suppressed in strain BR87 by an unlinked mutation in the env-2 locus (Sarubbi et al., 1975) its significance was unknown. Hence, the presence of this mutation among the clinical isolates studied herein indicates that it is important in HA⁺ in *vivo*. Moreover, this and a second missense mutation in codon 40, which also results in a radical amino acid substitution within the HTH motif of MtrR, suggests that this domain is important in the ability of MtrR to regulate levels of HA⁺ in gonococci. It is possible that amino acid replacements in the first (Ala-40 to Thr) or second (Gly-45 to Asp) helical domains reduces the ability of MtrR to bind to its DNA target site. We hypothesize that this reduction in MtrR binding allows for enhanced expression of the mtrCDE genes. The mechanism by which the missense mutation in codon 105 (His-105 to Tyr) in the mtrR gene of strains CH95 and 3035 results in HA⁺ is more difficult to understand since the amino acid replacement is outside of the proposed DNA-binding domain of MtrR. However, changes in amino acid sequence downstream of the HTH region could affect tertiary structure or subunit interactions that are important in DNA-binding. The impact of this mutation emphasizes the complexity of MtrR-mediated regulation of HA⁺ in gonococci.

High level HA⁺ in gonococci due to the mtr system is dependent on a single basepair deletion located within the mtrR promoter region. This deletion is located within a novel 13 bp inverted repeat sequence (Fig. 2); however, the significance of this repeat sequence and the impact of the deletion are not yet clear. Nevertheless, two hypotheses can be advanced, which are not mutually exclusive, that could account for their roles in determining HA⁺ in gonococci. First, the inverted repeat sequence could serve as a recognition site for MtrR and loss of a single basepair might reduce binding. Second, by de-
creasing the spacing between the −10 and −35 regions of the mtrR promoter by a single bp the fidelity of transcription could be affected by this deletion, resulting in loss of mtrR expression. It is important to note that transformants of strain FA19 bearing a null mutation in the mtrR gene exhibited different levels of HA^R depending on whether they contained an intact 13 bp inverted repeat sequence (Hagman et al., 1995). In this respect, strains bearing both a null mutation in mtrR and the single basepair deletion displayed higher levels of HA^R than isogenic strains containing the null mutation but having an intact 13 bp inverted repeat. Recent transcriptional studies indicate that this single basepair deletion inhibits expression of mtrR but enhances expression of the mtrCDE gene complex (K. E. Hagman & W. M. Shafer, unpublished results), a result that is consistent with the notion that the 13 bp inverted repeat sequence is a cis-acting transcriptional control element.

Mutations in the mtrR gene capable of transforming strain FA19 for enhanced resistance to HAs have been detected in rectal isolates and in strains isolated from patients with urogenital infections (Pan & Spratt, 1994; W. M. Shafer and others, unpublished observations), an observation that is consistent with the relatively high frequency at which HA^R strains are isolated (Morse et al., 1982). The capacity of gonococci to increase HA^R through mutations in the mtrR-coding region or the mtrR promoter region, or by an mtr-independent mechanism, provides this pathogen with several mechanisms to resist toxic agents acting transcriptional control element.

ACKNOWLEDGEMENTS

We thank P. F. Sparling for providing strains FA19, FA171 and BR87, L. Jones (Emory University Microchemical Facility) for preparing oligonucleotides, and L. Pucko for help in manuscript preparation. W. M. S. was supported by an Associate Career Scientist award from the VA Medical Research Service. This work was supported by PHS grant AI-21150 and funds from the VA Medical Research Service, both to W. M. S.

REFERENCES


Received 27 September 1994; revised 8 December 1994; accepted 5 January 1995.